Scarica l'app Stockscreener
1.02
1.92%
-0.02
Dopo l'orario di chiusura:
1.01
-0.01
-0.98%
Precedente Chiudi:
$1.04
Aprire:
$1.05
Volume 24 ore:
582.52K
Relative Volume:
1.70
Capitalizzazione di mercato:
$26.04M
Reddito:
-
Utile/perdita netta:
$-8.09M
Rapporto P/E:
-2.3427
EPS:
-0.4354
Flusso di cassa netto:
$-7.37M
1 W Prestazione:
-11.30%
1M Prestazione:
-27.14%
6M Prestazione:
+4.95%
1 anno Prestazione:
-28.67%
Intervallo 1D:
$1.0012
$1.05
Intervallo di 1 settimana:
$1.0012
$1.17
Portata 52W:
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Nome
NanoViricides Inc
Settore
Industria
Telefono
203-937-6137
Indirizzo
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.02 | 26.55M | 0 | -8.09M | -7.37M | -0.4354 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-16 | Iniziato | Alliance Global Partners | Buy |
| 2015-02-11 | Iniziato | Midtown Partners | Strong Buy |
NanoViricides Inc Borsa (NNVC) Ultime notizie
Operating cash flow per share of NanoViricides, Inc. – HAM:NV3P - TradingView
Gross margin % of NanoViricides, Inc. – HAM:NV3P - tradingview.com
CapEx per share of NanoViricides, Inc. – HAM:NV3P - TradingView
Total debt per share of NanoViricides, Inc. – HAM:NV3P - TradingView
Basic earnings per share (basic EPS) of NanoViricides, Inc. – HAM:NV3P - TradingView
NanoViricides Registers Phase II Ebola Trial for Oral Antiviral NV-387 in DRC - citybuzz.co
NV3P Forecast — Price Target — Prediction for 2027 - TradingView
News by ACCESS Newswire on TradingView, 2026-09-08 - TradingView
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles - ACCESS Newswire
NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola - Stocktwits
Nanoviricides Stock Price Forecast. Should You Buy NNVC? - StockInvest.us
NanoViricides (AMEX: NNVC) May Generate Up to $4.4 Million Through Warrant Exercises - Kalkine Media
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for MeaslesEnables Priority Review Voucher - ACCESS Newswire
U.S. measles cases reach 2,903 by Aug. 27 as NanoViricides prepares a trial - Stock Titan
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo - ACCESS Newswire
NanoViricides Inc. (NNVC) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
NanoViricides (NNVC) Chart: Ends Lower by 3.08% at $1.29 in the Latest Session; Technical View: the Supplied Trading Band Runs From $1.23 to $1.35 in the Available RecordFibonacci Fan - vinanet.vn
NanoViricides (NNVC) Results Breakdown: EPS Exceeds Its Estimate; After Earnings: Shares Move Higher 1.53%Subscription Growth Report - dars.gov.et
NanoViricides (NNVC) Technicals: Ends Up by 1.53% at $1.33 in the Latest Reading; Immediate View: Support at $1.26 and Resistance at $1.40 Frame the Range in the Available RecordWyckoff Accumulation - vinanet.vn
NanoViricides (NYSE American: NNVC) sets up warrant resale, up to $4.4M cash - Stock Titan
NanoViricides (NNVC) Levels: Finishes 0.82% Down at $1.33 at the Close; Chart Watch: Traders Can Monitor the $1.26-$1.40 Range in the Current UpdateHigh Conviction Picks - vinanet.vn
NanoViricides Prepares for Phase II Ebola Trial of Oral Drug Candidate in DRC - citybuzz -
Ebola outbreak has killed 2,325 as oral drug trial nears - Stock Titan
NNVC Stock Up 17% Today: What’s Driving The Rally? - Stocktwits
ETFs Investing in NanoViricides, Inc. Stocks - TradingView
NNVC Q2 2026 Earnings: EPS Surprise of 22.97% Bolsters Sentiment as Shares Rise 1.47%Interim Report - vinanet.vn
NNVC Q2 2026 Earnings: Narrower-Than-Expected Loss Marks 22.97% Positive SurpriseQuarterly Earnings Report - vinanet.vn
NanoViricides (NNVC) Edges Lower to $1.36 as Antiviral Developer Holds Support ZoneNews Sentiment - vinanet.vn
NanoViricides (NNVC) Slips to $1.36 as Biotech Micro-Cap Tests Key Support ZoneImpulse Wave - vinanet.vn
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak - ACCESS Newswire
NanoViricides (NNVC) Dips 2.5% to $1.36 as Shares Approach Critical $1.29 SupportCollar Trade - vinanet.vn
NanoViricides, Inc. (NNVC) Stock Price, News, Quote & History - Yahoo! Finance Canada
NanoViricides Gets Approval for Phase II Ebola Trial in DRC, Offering Oral Treatment Option - citybuzz.co
NanoViricides wins DRC approval for Phase II trial of NV-387 oral gummies for Ebola treatment - Bitget
DRC Ebola Outbreak Stands at 4,141 Cases as Oral Trial Gets Approval - Stock Titan
NNVC Q2 2026 Earnings: Loss Narrower Than Expected at -$0.11 Per Share, Stock Slips 2.1%Pre-Announcement Alert - vinanet.vn
NanoViricides (NNVC) Holds Gains at $1.54 as Shares Consolidate Between Support and ResistanceSweep Order Flow - vinanet.vn
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Watertown Public Opinion
NanoViricides (NNVC) Q2 2026 Earnings: Narrower-Than-Expected Loss but Shares Slip 1.94%Dividend Earnings Report - vinanet.vn
NanoViricides Inc (NNVC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NanoViricides Announces $3.8 Million Registered Direct Offering - TipRanks
NanoViricides Raises $3.8 Million in Registered Direct Offering; Adds Placement Agent and 30-Day Lock-Up - TradingView
Ebola outbreak death toll tops 1,300 as drug trial awaits approval - Stock Titan
NanoViricides Seeks Regulatory Approval for Ebola Trial of NV-387 Oral Gummies in DRC - citybuzz.co
NanoViricides Inc (NNVC) Cash Flow - TradingKey
EDGAR Filing Documents for 0001104659-26-086797 - SEC.gov
Form 424B5 NanoViricides Inc For: 27 July By Investing.com - Investing.com Canada
Form 424B5 NANOVIRICIDES, INC. - StreetInsider
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering - ACCESS Newswire
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola - ACCESS Newswire
NanoViricides, Inc. Revenue Breakdown – AMEX:NNVC - TradingView
NanoViricides Inc Azioni (NNVC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):